Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ESMO 2017

Videos
News
ESMO 2017 highlights on managing difficult to treat cancers
Prof Richard Finn, Prof Viktor Grünwald, Prof Arndt Vogel, Prof René Adam
ESMO 2017 highlights on managing difficult to treat cancers ( Prof Richard Finn, Prof Viktor Grünwald, Prof Arndt Vogel, Prof René Adam )
14 Sep 2017
ESMO 2017 roundup with Dr Bishal Gyawali (1/2)
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2017 roundup with Dr Bishal Gyawali (1/2) ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
11 Sep 2017
ESMO 2017 roundup with Dr Bishal Gyawali (2/2)
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2017 roundup with Dr Bishal Gyawali (2/2) ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
11 Sep 2017
Pembrolizumab falls short of endpoints in KEYNOTE 40
Dr Ezra Cohen - UC San Diego Health, San Diego, USA
Pembrolizumab falls short of endpoints in KEYNOTE 40 ( Dr Ezra Cohen - UC San Diego Health, San Diego, USA )
11 Sep 2017
ARIEL3: Rucaparib as maintenance therapy in recurrent ovarian cancer patients
Prof Jonathan Ledermann - University College London Hospitals, London, UK
ARIEL3: Rucaparib as maintenance therapy in recurrent ovarian cancer patients ( Prof Jonathan Ledermann - University College London Hospitals, London, UK )
11 Sep 2017
Initial results of inhibitor combination against breast and gynaecologic cancers
Dr Shannon Westin - MD Anderson Cancer Center, Houston, Texas
Initial results of inhibitor combination against breast and gynaecologic cancers ( Dr Shannon Westin - MD Anderson Cancer Center, Houston, Texas )
11 Sep 2017
Patient empowerment and quality of life
Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium
Patient empowerment and quality of life ( Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium )
11 Sep 2017
Chemoradiation remains best treatment for locally advanced cervical cancer
Prof Sudeep Gupta - Tata Memorial Hospital, Mumbai, India
Chemoradiation remains best treatment for locally advanced cervical cancer ( Prof Sudeep Gupta - Tata Memorial Hospital, Mumbai, India )
11 Sep 2017
LORELEI trial of letrozole and taselisib for ER positive breast cancer
Dr Cristina Saura - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
LORELEI trial of letrozole and taselisib for ER positive breast cancer ( Dr Cristina Saura - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Sep 2017
Fertility-preserving procedures in BRCA mutation-positive breast cancer
Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium
Fertility-preserving procedures in BRCA mutation-positive breast cancer ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )
11 Sep 2017
Nivolumab and ipilimumab for metastatic kidney cancer
Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France
Nivolumab and ipilimumab for metastatic kidney cancer ( Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France )
11 Sep 2017
Biological insight in new drug combinations
Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biological insight in new drug combinations ( Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Sep 2017
BRIM8: Vemurafenib in high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
BRIM8: Vemurafenib in high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
Durvalumab in novel combinations for head and neck cancer
Dr Ezra Cohen - UC San Diego Health, San Diego, USA
Durvalumab in novel combinations for head and neck cancer ( Dr Ezra Cohen - UC San Diego Health, San Diego, USA )
11 Sep 2017
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Expert commentary on melanoma immunotherapy latest
Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard
Expert commentary on melanoma immunotherapy latest ( Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard )
11 Sep 2017
Vemurafenib for high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
Vemurafenib for high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
Dabrafenib plus trametinib for stage III mutant melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Dabrafenib plus trametinib for stage III mutant melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Nivolumab vs ipilimumab for high risk melanoma patients
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Nivolumab vs ipilimumab for high risk melanoma patients ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
ESMO 2017: Prostate cancer highlights
Prof Karim Fizazi, Prof Stephane Oudard, Dr Bertrand Tombal & Prof Maria De...
ESMO 2017: Prostate cancer highlights ( Prof Karim Fizazi, Prof Stephane Oudard, Dr Bertrand Tombal & Prof Maria De Santis )
10 Sep 2017
The role of tumour marker testing in early diagnosis
Dr Craig Barrington - South West Wales Cancer Centre, UK
The role of tumour marker testing in early diagnosis ( Dr Craig Barrington - South West Wales Cancer Centre, UK )
10 Sep 2017
The METRIC trial of trametinib, five years on
Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany
The METRIC trial of trametinib, five years on ( Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany )
10 Sep 2017
Patient perceptions of chemotherapy side effects differ over time and treatment
Dr Beyhan Ataseven - Kliniken Essen-Mitte, Essen, Germany
Patient perceptions of chemotherapy side effects differ over time and treatment ( Dr Beyhan Ataseven - Kliniken Essen-Mitte, Essen, Germany )
10 Sep 2017
Treatment choices in thyroid cancer
Prof Makoto Tahara - National Cancer Center Hospital East, Kashiwanoha, Japan
Treatment choices in thyroid cancer ( Prof Makoto Tahara - National Cancer Center Hospital East, Kashiwanoha, Japan )
10 Sep 2017
Clinical advances in treating colorectal cancer
Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany
Clinical advances in treating colorectal cancer ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )
10 Sep 2017
Impact of licensing and reimbursement discrepancies on cancer care in Europe...
Jan McKendrick - PRMA Consulting Ltd, Fleet, UK
Impact of licensing and reimbursement discrepancies on cancer care in Europe and Canada ( Jan McKendrick - PRMA Consulting Ltd, Fleet, UK )
10 Sep 2017
ABP 980, a biosimilar antibody for trastuzumab
Dr Richard Markus - Amgen, Conejo Valley, USA
ABP 980, a biosimilar antibody for trastuzumab ( Dr Richard Markus - Amgen, Conejo Valley, USA )
10 Sep 2017
New strategies in melanoma care
Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands
New strategies in melanoma care ( Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2017
Real-world productivity of advanced gastric cancer patients
Dr Marta Contente - Bristol-Myers Squibb, Uxbridge, UK
Real-world productivity of advanced gastric cancer patients ( Dr Marta Contente - Bristol-Myers Squibb, Uxbridge, UK )
10 Sep 2017
Abemaciclib for advanced breast cancer
Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy
Abemaciclib for advanced breast cancer ( Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy )
10 Sep 2017
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer
Dr Evandro de Azambuja - Jules Bordet Institute, Brussels, Belgium
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer ( Dr Evandro de Azambuja - Jules Bordet Institute, Brussels, Belgium )
10 Sep 2017
CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic...
Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France
CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma ( Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France )
10 Sep 2017
RANGE: docetaxel with or without ramucirumab for metastatic urothelial carcinoma
Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA
RANGE: docetaxel with or without ramucirumab for metastatic urothelial carcinoma ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA )
10 Sep 2017
Chemotherapy then surgery no better than concomitant chemoradiation for...
Prof Sudeep Gupta - Tata Memorial Hospital, Mumbai, India
Chemotherapy then surgery no better than concomitant chemoradiation for advanced cervical cancer ( Prof Sudeep Gupta - Tata Memorial Hospital, Mumbai, India )
10 Sep 2017
MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced...
Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy
MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer ( Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy )
10 Sep 2017
ESMO 2017: New prostate data from STAMPEDE
Prof Martin Bögemann and Prof Nicholas James
ESMO 2017: New prostate data from STAMPEDE ( Prof Martin Bögemann and Prof Nicholas James )
10 Sep 2017
RANGE trial of ramucirumab for urothelial cancer
Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA
RANGE trial of ramucirumab for urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA )
10 Sep 2017
Small node-negative breast cancers may retain aggressive characteristics
Dr Konstantinos Tryfonidis - European Organisation for Research and Treatment...
Small node-negative breast cancers may retain aggressive characteristics ( Dr Konstantinos Tryfonidis - European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium )
9 Sep 2017
Adaptive TONIC trial of nivolumab combinations for breast cancer
Dr Marleen Kok - Netherlands Cancer Institute, Amsterdam, Netherlands
Adaptive TONIC trial of nivolumab combinations for breast cancer ( Dr Marleen Kok - Netherlands Cancer Institute, Amsterdam, Netherlands )
9 Sep 2017
Panitumumab triplet therapy in colorectal cancer
Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany
Panitumumab triplet therapy in colorectal cancer ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )
9 Sep 2017
Long term efficacy of denosumab for giant cell bone tumours
Prof Emanuela Palmerini - Rizzoli Orthopedic Institute, Bologna, Italy
Long term efficacy of denosumab for giant cell bone tumours ( Prof Emanuela Palmerini - Rizzoli Orthopedic Institute, Bologna, Italy )
9 Sep 2017
Returning to work after cancer
Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway
Returning to work after cancer ( Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway )
9 Sep 2017
Financial and ethical safety in cancer care
Dr Stefan Rauh - Hospital Center Emile Mayrisch, Esch-sur-Alzette, Luxembourg
Financial and ethical safety in cancer care ( Dr Stefan Rauh - Hospital Center Emile Mayrisch, Esch-sur-Alzette, Luxembourg )
9 Sep 2017
STORM trial to identify genetic variability in metastatic breast cancer
Dr David Cox - Cancer Research Center of Lyon, Lyon, France
STORM trial to identify genetic variability in metastatic breast cancer ( Dr David Cox - Cancer Research Center of Lyon, Lyon, France )
9 Sep 2017
The UNICANCER-NeoPAL study of letrozole and palbociclib in luminal cancer
Dr Paul Cottu - Institut Curie, Paris, France
The UNICANCER-NeoPAL study of letrozole and palbociclib in luminal cancer ( Dr Paul Cottu - Institut Curie, Paris, France )
9 Sep 2017
Phase Ib/II trial of combination PD-1 therapy against kidney cancer
Dr Chung-Han Lee - Memorial Sloan Kettering Cancer Center, New York, USA
Phase Ib/II trial of combination PD-1 therapy against kidney cancer ( Dr Chung-Han Lee - Memorial Sloan Kettering Cancer Center, New York, USA )
9 Sep 2017
STAMPEDE: Abiraterone acetate plus prednisolone or docetaxel
Matthew Sydes - Medical Research Council, London, UK
STAMPEDE: Abiraterone acetate plus prednisolone or docetaxel ( Matthew Sydes - Medical Research Council, London, UK )
9 Sep 2017
Problems with care: a patients perspective
Ana Kogan Wais - Ewing sarcoma patient, Madrid, Spain
Problems with care: a patients perspective ( Ana Kogan Wais - Ewing sarcoma patient, Madrid, Spain )
9 Sep 2017
Reduced work ability in cancer survivors
Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway
Reduced work ability in cancer survivors ( Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway )
9 Sep 2017
Problems with survivorship care in Europe
Prof Francesco De Lorenzo - University of Naples Federico II, Naples, Italy
Problems with survivorship care in Europe ( Prof Francesco De Lorenzo - University of Naples Federico II, Naples, Italy )
9 Sep 2017
Underprovision and inequality of specialised cancer care
Dr Emmanouil Saloustros - General Hospital of Heraklion 'Venizelio', Crete...
Underprovision and inequality of specialised cancer care ( Dr Emmanouil Saloustros - General Hospital of Heraklion 'Venizelio', Crete, Greece )
9 Sep 2017
Regorafenib versus lomustine for relapsed glioblastoma
Dr Giuseppe Lombardi - Istituto Oncologico Veneto, Padova, Italy
Regorafenib versus lomustine for relapsed glioblastoma ( Dr Giuseppe Lombardi - Istituto Oncologico Veneto, Padova, Italy )
9 Sep 2017
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer
Prof Miguel Martin - Hospital General Universitario Gregorio Marañón, Madrid...
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer ( Prof Miguel Martin - Hospital General Universitario Gregorio Marañón, Madrid, Spain )
9 Sep 2017
PACIFIC trial of durvalumab for stage III NSCLC
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
PACIFIC trial of durvalumab for stage III NSCLC ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
9 Sep 2017
Questioning the role of CT-scan in NSCLC post-surgery follow-up
Prof Virginie Westeel - University of Franche-Comté, Besançon, France
Questioning the role of CT-scan in NSCLC post-surgery follow-up ( Prof Virginie Westeel - University of Franche-Comté, Besançon, France )
9 Sep 2017
Osimertinib suitable for first line EGFRm lung cancer
Dr Suresh Ramalingam - Winship Cancer Institute, Atlanta, USA
Osimertinib suitable for first line EGFRm lung cancer ( Dr Suresh Ramalingam - Winship Cancer Institute, Atlanta, USA )
9 Sep 2017
FLAURA study of osimertinib versus TKI for 1st line NSCLC
Dr Suresh Ramalingam - Winship Cancer Institute, Druid Hills, USA
FLAURA study of osimertinib versus TKI for 1st line NSCLC ( Dr Suresh Ramalingam - Winship Cancer Institute, Druid Hills, USA )
9 Sep 2017
Follow-up on the IFCT-0302 trial
Prof Virginie Westeel - University of Franche-Comté, Besançon, France
Follow-up on the IFCT-0302 trial ( Prof Virginie Westeel - University of Franche-Comté, Besançon, France )
9 Sep 2017
PACIFIC trial of durvalumab for lung cancer
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
PACIFIC trial of durvalumab for lung cancer ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
9 Sep 2017
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective
Prof Kimberly Blackwell, Prof Hope Rugo, Prof Peter Schmid, Dr Mark Verrill
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective ( Prof Kimberly Blackwell, Prof Hope Rugo, Prof Peter Schmid, Dr Mark Verrill )
8 Sep 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation